• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA OKs Endo’s opioid cheek patch licensed from BioDelivery Sciences

FDA OKs Endo’s opioid cheek patch licensed from BioDelivery Sciences

October 26, 2015 By MassDevice

Belbuca(Reuters) — BioDelivery Sciences International said the FDA approved its opioid cheek patch for chronic pain, sending the drugmaker’s shares up 23% in premarket trading today.

Endo International (NSDQ:ENDP) licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012.

Belbuca is an opioid film patch and aims to treat patients with chronic pain who need round-the-clock treatment and for whom current alternatives do not suffice.

The patch is expected to be commercially available in the United States by the 1st quarter ending March in 7 dosages, BioDelivery said.

Belbuca is placed on the inner lining of the cheek, leading to faster delivery of analgesic drug buprenorphine directly into the bloodstream.

Buprenorphine has a lower abuse potential than most opioid medications. The Belbuca treatment can also prevent misuse through snorting or injecting as the film patch is difficult to crush or liquefy.

Given the lower possibilities of misuse as seen with buprenorphine, physicians can write a six-month prescription as opposed to writing one on a strict monthly basis.

“It (buprenorphine) is an easier drug to write,” Laidlaw analyst Jim Molloy said.

Since most of the drug is absorbed through the cheek and with little going through the digestive tract, Belbuca could potentially lead to lower constipation, a common side effect that most oral drugs are known to cause, Molloy said.

Molloy expects the treatment to rake in peak U.S. sales of about $450 million by 2018 for Endo, and about $80 million for BioDelivery. He said Belbuca accounts for $12 of his $17 price target on BioDelivery’s shares.

The abuse of opioids, a class of drugs that include heroin and prescription painkillers, has long been a concern in the U.S. An overdose of prescription painkillers can produce euphoric highs and even disrupt parts of the brain that control breathing.

The approval comes a little more than a month after the FDA staff flagged dosage concerns over Collegium Pharmaceutical’s opioid drug, Xtampza, and Purdue Pharma’s fast-acting oxycodone painkiller.

The approval also triggers a $50 million milestone payment by Endo to BioDelivery as part of a licensing agreement signed in 2012. The company will also receive royalties on U.S. net sales of the drug.

BioDelivery’s shares, which closed at $5.28 Oct. 23, were at $6.50 before the bell.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pain Management, Regulatory/Compliance Tagged With: BioDelivery Sciences International, Endo Health

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy